Table 3.

Dosages of targeted treatments approved for AxSpA/PsA, Crohn’s disease and Ulcerative Colitis.

	AxSpA & PsA	Crohn’s disease	Ulcerative Colitis
Infliximab	Loading dosage	Loading dosage
	5 mg/kg at 0, 2, 6 weeks	5 mg/kg at 0, 2, 6 weeks
	Maintenance dosage	Maintenance dosage
	5mg/kg every 6–8 weeks (AxSpA) or 8 weeks (PsA)	5mg/kg every 8 weeks
Adalimumab	40 mg every 2 weeks	Loading dosage 80 mg (week 0), 40mg (week 2) 160 mg (week 0), 80mg (week 2)*	Loading dosage 160 mg (week 0), 80mg (week 2)
		Maintenance dosage 40 mg every 2 weeks** 80mg every 2 weeks or 40mg every week***	Maintenance dosage 40 mg every 2 weeks** 80mg every 2 weeks or 40mg/week***
Golimumab	50 mg every month 100 mg every month, if body weight >100kg**		Loading dosage 200 mg (week 0), 100mg (week 2)
			Maintenance dosage 50–100mg† every 4 weeks (EU label) US 100mg every 4 weeks (US label)
Certolizumab pegol	Loading dosage	Loading dosage
	400mg at week 0, 2, 4	400mg at week 0, 2, 4
	Maintenance dosage	Maintenance dosage
	200 mg every 2 weeks	200 mg every 2 weeks
Ustekinumab	PsA only: 45mg sc at weeks 0, 4, then every12 weeks 90mg sc at weeks 0, 4, then every12 weeks, if body weight >100 kg	Loading dosage
		6mg/kg iv (week 0), 90mg sc at week 8
		90 mg every 8–12 weeks sc ‡ (EU label) 90 mg every 8 weeks sc (US label)
Tofacitinib	5 mg twice daily		Loading dosage
			10 mg twice daily for 8–16 weeks¶
			Maintenance dosage
			5–10 mg twice daily§

^*In case fast response is pursued. The only approved loading dosage in the US

^**The only approved maintenance dosage in the US

^***In case of inadequate response to the lower dosage (EU label)

^†In case of inadequate response to the lower dosage or body weight ≥80kg

^‡In case of inadequate response to the 12-week schedule

^¶In case of inadequate response during the first 8 weeks

^§In case of loss of response dosage may be increased to 10mg twice daily for the shortest time necessary; dosage of the extended-release formulation is not shown